论文部分内容阅读
目的:观察瑞舒伐他汀联合尼可地尔对冠状动脉慢血流(CSF)的疗效。方法:收集冠状动脉造影诊断为CSF患者64例,随机分为对照组和治疗组各32例。对照组予阿司匹林、瑞舒伐他汀,治疗组在对照组基础上加用尼可地尔,观察治疗4、12周后2组患者胸痛症状改善程度,并检测血浆脂联素(APN)、超敏C反应蛋白(hs-CRP)及肿瘤坏死因子-α(TNF-α)等指标。结果:治疗4周后2组患者胸痛症状均较用药前改善,血浆APN水平较用药前升高;治疗12周后升高更明显,且治疗组升高程度均大于对照组(P<0.01),2组患者治疗4周后hs-CRP及TNF-α水平较用药前降低,治疗12周后降低更明显(P<0.01),且治疗组下降程度均大于对照组(P<0.01)。结论:瑞舒伐他汀联合尼可地尔对缓解CSF患者的胸痛症状疗效显著,可显著提高CSF患者的血浆APN水平,降低血浆hs-CRP和TNF-α水平。
Objective: To observe the effect of rosuvastatin combined with nicorandil on coronary artery (CSF). Methods: Sixty-four patients with CSF diagnosed by coronary angiography were randomly divided into control group and treatment group with 32 cases each. The patients in the control group were given aspirin and rosuvastatin. The patients in the treatment group were given Nicorandil on the basis of the control group. The improvement of chest pain symptom was observed in the two groups after 4 and 12 weeks of treatment. The levels of plasma adiponectin (APN) Hs-CRP and tumor necrosis factor-α (TNF-α) and other indicators. Results: After 4 weeks of treatment, the symptoms of chest pain in both groups were improved compared with before treatment, and the plasma APN level was higher than before treatment. After 12 weeks of treatment, the symptoms of chest pain were more obvious, and the levels of the treatment group were higher than those of the control group (P <0.01); 2 After 4 weeks of treatment, the levels of hs-CRP and TNF-α in the patients were lower than those before treatment, and the levels of hs-CRP and TNF-α decreased more obviously after 12 weeks of treatment (P <0.01), and decreased more in the treatment group than those in the control group (P <0.01). Conclusion: Rosuvastatin combined with Nicorandil has a significant effect on relieving chest pain in patients with CSF salvage, which can significantly increase the level of plasma APN and decrease the levels of plasma hs-CRP and TNF-α in patients with CSF.